BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial

Tags: | June 1st, 2016

Author: Butler K, Inshaw J, Ford D, et al.

Published in:  Health Technol Assess2016;20(49):1-108.

Abstract: The trial showed that short-cycle antiretroviral therapy was not inferior to continuous therapy in suppressing human immunodeficiency viral load in young people taking efavirenz-based first-line therapy and a viral load of < 50 copies/ml, with similar resistance, safety and inflammatory marker profiles.